Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.~* Biopsy confirmed active lupus nephritis.~* Clinically active lupus renal disease at screening requiring /receiving induction therapy with Standard of Care medications.~* Autoantibody-positive.~Key Exclusion Criteria:~* Pregnant or nursing.~* On dialysis within the past year.~* Treatment with belimumab within the past year .~* Receipt of induction therapy with cyclophosphamide within 3 months prior to induction therapy for the study.~* Receipt of any B cell targeted therapy (for example, rituximab), investigational biological agent within the past year.~* Severe active central nervous system (CNS) lupus.~* Required management of acute or chronic infections within the past 60 days.~* Current drug or alcohol abuse or dependence.~* Tested positive for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.~* History of severe allergic reaction to contrast agents or biological medicines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo plus standard therapy (Type: PLACEBO_COMPARATOR): Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
- Belimumab 10 mg/kg plus standard therapy (Type: EXPERIMENTAL): Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).